Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Catechol-O-methyl transferase (COMT) inhibitors in patients with Parkinson's disease: is COMT genotype a useful indicator of clinical efficacy?

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice - 1 Jan 2003

Rinne Juha O, Ulmanen Ismo, Lee Myung-Sik

Abstract excerpt

In clinical practice, two potent and selective catechol-O-methyl transferase (COMT) inhibitors are available for the control of motor fluctuation in patients with Parkinson's disease. However, because of the complexity of fluctuating motor symptoms, it is difficult to evaluate the clinical efficacy of COMT inhibitors in each individual. Therefore, an objective factor predicting the clinical efficacy of COMT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catechol O-Methyltransferase
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COMT gene

Share to Gene Expression Regulation, Enzymologic

Share to Genotype

Share to Parkinson Disease

Source

Identifiers

PMID: 12562212

Genes

COMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Catechol-O-methyl transferase (COMT) inhibitors in patients with Parkinson's disease: is COMT genotype a useful indicator of clinical efficacy?PMID 12562212Read ↗

COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.Semantic proximity Read ↗

Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.Semantic proximity Read ↗

Roles of functional catechol-O-methyltransferase genotypes in Chinese patients with Parkinson’s diseaseSemantic proximity Read ↗

Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease.Semantic proximity Read ↗

The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.Semantic proximity Read ↗

Catechol-O-methyltransferase and Parkinson's disease.Semantic proximity Read ↗

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complicationsSemantic proximity Read ↗

COMT gene and risk for Parkinson's disease: a systematic review and meta-analysis.Semantic proximity Read ↗

Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson's disease.Semantic proximity Read ↗

Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.Semantic proximity Read ↗

MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.Semantic proximity Read ↗

Association of catechol-o-methyltransferase polymorphism (Val108/158Met) with Parkinson's disease: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.